Trials / Completed
CompletedNCT00809042
Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia
The Effect of Combination Therapy of Hydroxyurea With L- Carnitine and Magnesium Chloride on he-Matologic Parameters and Cardiac Function of β-Thalassemia Intermedia Patients.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Shiraz University of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 4 Years – 35 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is determination of the efficacy of combination of hydroxyurea with L-carnitine or magnesium in improving hematologic parameters and cardiac status in patients with β-thalassemia intermedia in comparison with hydroxyurea alone .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | hydroxyurea | Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). |
| DRUG | L-carnitine and hydroxyurea | Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day). |
| DRUG | hydroxyurea and magnesium chloride | Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day. |
| DRUG | hydroxyurea,L-carnitine and magnesium chloride | Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2007-11-01
- Completion
- 2007-12-01
- First posted
- 2008-12-16
- Last updated
- 2008-12-16
Locations
1 site across 1 country: Iran
Source: ClinicalTrials.gov record NCT00809042. Inclusion in this directory is not an endorsement.